Skip to main content
Journal cover image

Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment

Publication ,  Journal Article
Niyazov, DM; Kahler, SG; Frye, RE
Published in: Molecular Syndromology
July 1, 2016

Mitochondrial disease refers to a heterogeneous group of disorders resulting in defective cellular energy production due to abnormal oxidative phosphorylation (oxphos). Primary mitochondrial disease (PMD) is diagnosed clinically and ideally, but not always, confirmed by a known or indisputably pathogenic mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) mutation. The PMD genes either encode oxphos proteins directly or they affect oxphos function by impacting production of the complex machinery needed to run the oxphos process. However, many disorders have the 'mitochondrial' phenotype without an identifiable mtDNA ornDNA mutation or they have a variant of unknown clinical significance. Secondary mitochondrial dysfunction (SMD) can be caused by genes encoding neither function nor production of the oxphos proteins and accompanies many hereditarynon-mitochondrial diseases. SMD may also be due to nongenetic causes such as environmental factors. In our practice, we see many patients with clinical signs of mitochondrial dysfunction based on phenotype, biomarkers,imaging, muscle biopsy, or negative/equivocal mtDNA or nDNA test results. In these cases, it is often tempting to assign a patient's phenotype to 'mitochondrial disease', but SMD is often challenging to distinguish from PMD. Fortunately, rapid advances in molecular testing, made possible by next generation sequencing, have been effective at least in some cases in establishing accurate diagnoses to distinguish between PMD and SMD. This is important, since their treatments and prognoses can be quite different. However, even in the absence of the ability to distinguish between PMD and SMD, treating SMD with standard treatments for PMD can be effective. We review the latest findings regarding mitochondrial disease/dysfunction and give representative examples in which differentiation between PMD and SMD has been crucial for diagnosis and treatment.

Duke Scholars

Published In

Molecular Syndromology

DOI

EISSN

1661-8777

ISSN

1661-8769

Publication Date

July 1, 2016

Volume

7

Issue

3

Start / End Page

122 / 137

Related Subject Headings

  • 3202 Clinical sciences
  • 3105 Genetics
  • 1103 Clinical Sciences
  • 0604 Genetics
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Niyazov, D. M., Kahler, S. G., & Frye, R. E. (2016). Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment. Molecular Syndromology, 7(3), 122–137. https://doi.org/10.1159/000446586
Niyazov, D. M., S. G. Kahler, and R. E. Frye. “Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment.” Molecular Syndromology 7, no. 3 (July 1, 2016): 122–37. https://doi.org/10.1159/000446586.
Niyazov DM, Kahler SG, Frye RE. Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment. Molecular Syndromology. 2016 Jul 1;7(3):122–37.
Niyazov, D. M., et al. “Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment.” Molecular Syndromology, vol. 7, no. 3, July 2016, pp. 122–37. Scopus, doi:10.1159/000446586.
Niyazov DM, Kahler SG, Frye RE. Primary Mitochondrial Disease and Secondary Mitochondrial Dysfunction: Importance of Distinction for Diagnosis and Treatment. Molecular Syndromology. 2016 Jul 1;7(3):122–137.
Journal cover image

Published In

Molecular Syndromology

DOI

EISSN

1661-8777

ISSN

1661-8769

Publication Date

July 1, 2016

Volume

7

Issue

3

Start / End Page

122 / 137

Related Subject Headings

  • 3202 Clinical sciences
  • 3105 Genetics
  • 1103 Clinical Sciences
  • 0604 Genetics